Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 513,629
  • Shares Outstanding, K 39,419
  • Annual Sales, $ 0 K
  • Annual Income, $ -85,810 K
  • 60-Month Beta 0.56
  • Price/Sales 78.57
  • Price/Cash Flow N/A
  • Price/Book 2.60
Trade STOK with:

Options Overview Details

View History
  • Implied Volatility 97.93% ( +46.04%)
  • Historical Volatility 61.97%
  • IV Percentile 67%
  • IV Rank 60.32%
  • IV High 160.76% on 06/21/22
  • IV Low 2.40% on 07/18/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 391
  • Volume Avg (30-Day) 19
  • Put/Call OI Ratio 10.45
  • Today's Open Interest 1,683
  • Open Int (30-Day) 1,709

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.70
  • Number of Estimates 6
  • High Estimate -0.67
  • Low Estimate -0.73
  • Prior Year -0.61
  • Growth Rate Est. (year over year) -14.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.00 +0.23%
on 09/23/22
17.60 -25.97%
on 08/24/22
-3.80 (-22.58%)
since 08/23/22
3-Month
12.25 +6.37%
on 06/29/22
22.87 -43.03%
on 08/10/22
-0.90 (-6.46%)
since 06/23/22
52-Week
9.55 +36.51%
on 06/16/22
33.06 -60.59%
on 11/22/21
-14.23 (-52.20%)
since 09/23/21

Most Recent Stories

More News
Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...

STOK : 13.03 (-12.55%)
4 Potential Short Squeeze Stocks to Avoid This Week

The meme stock frenzy of 2021 seems to be returning, with several fundamentally weak stocks skyrocketing lately. However, since the market is expected to remain under pressure in the coming months, potential...

LMND : 21.49 (+4.37%)
SIEN : 0.5346 (+1.91%)
STOK : 13.03 (-12.55%)
WE : 3.12 (-4.88%)
How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 91%

The average of price targets set by Wall Street analysts indicates a potential upside of 90.7% in Stoke Therapeutics, Inc. (STOK). While the effectiveness of this highly sought-after metric is questionable,...

STOK : 13.03 (-12.55%)
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 10% and 19.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

STOK : 13.03 (-12.55%)
TARS : 16.01 (-0.12%)
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported...

STOK : 13.03 (-12.55%)
Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...

STOK : 13.03 (-12.55%)
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported...

STOK : 13.03 (-12.55%)
Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates

Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.

VRTX : 283.45 (-1.01%)
ACAD : 16.75 (-1.41%)
VYGR : 5.57 (-6.23%)
STOK : 13.03 (-12.55%)
Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...

STOK : 13.03 (-12.55%)
Stoke Therapeutics is Now Oversold (STOK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

STOK : 13.03 (-12.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford,...

See More

Key Turning Points

3rd Resistance Point 16.32
2nd Resistance Point 15.65
1st Resistance Point 14.34
Last Price 13.03
1st Support Level 12.36
2nd Support Level 11.69
3rd Support Level 10.38

See More

52-Week High 33.06
Fibonacci 61.8% 24.08
Fibonacci 50% 21.30
Fibonacci 38.2% 18.53
Last Price 13.03
52-Week Low 9.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar